Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-04-06Clinical Trial Update: Priming Immunotherapy in Advanced Disease With Radiation [Phase 2]
This is a Phase 2 clinical trial update evaluating priming immunotherapy in combination with radiation for advanced disease. Results have be…
-
CLINICAL_TRIALS trial_result · 2025-04-06Clinical Trial Update: Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation [Phase 1]
Phase 1 study of MRTX1133 in KRAS G12D-mutant solid tumors has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer [Phase 2]
This Phase 2 neoadjuvant study of anti-PD-1 immunotherapy in resectable non-small cell lung cancer has completed enrollment and posted resul…
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: Study of XB002 in Subjects With Solid Tumors (JEWEL-101) [Phase 1]
JEWEL-101 is a Phase 1 trial of XB002 in patients with solid tumors, covering multiple indications. The study has completed.
-
CLINICAL_TRIALS trial_result · 2025-04-03Clinical Trial Update: A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) [Phase 3]
Results from the Phase 3 LAURA trial evaluating osimertinib after chemoradiation in stage III unresectable non-small cell lung cancer have b…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-04-03Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer [Phase 1]
Phase 1 trial evaluating alflutinib in advanced non-small cell lung cancer reports safety, tolerability, pharmacokinetics and anti-tumor act…
-
CLINICAL_TRIALS trial_result · 2025-04-03Clinical Trial Update: Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M [Phase 2]
A Phase 2 trial evaluating alflutinib in EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer has been terminated. …
-
CLINICAL_TRIALS trial_result · 2025-04-03Clinical Trial Update: AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations [NA]
The AST2818 trial in advanced non-small cell lung cancer with EGFR mutations has been terminated; no further results are provided in the upd…
-
CLINICAL_TRIALS trial_result · 2025-04-02Clinical Trial Update: Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients [Phase 2]
A Phase 2 neoadjuvant trial for EGFR-mutated non-small cell lung cancer (Neo-DIANA) was terminated, with results posted in 2025.
-
CLINICAL_TRIALS trial_result · 2025-04-02Clinical Trial Update: A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies [Phase 1, Phase 2]
Phase 1/2 open-label study evaluating Alomfilimab (KY1044) alone and with atezolizumab in multiple advanced cancers. The trial was terminate…
-
CLINICAL_TRIALS trial_result · 2025-04-02Clinical Trial Update: TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors [Phase 1, Phase 2]
Clinical trial update for TT-10 and TT-4 (Portage Biotech) exploring single-agent and combination therapy in advanced solid tumors, with rec…
-
CLINICAL_TRIALS trial_result · 2025-04-01Clinical Trial Update: Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating binimetinib in combination with hydroxychloroquine for advanced KRAS-mutant non-small cell lung cancer has complete…
-
CLINICAL_TRIALS trial_result · 2025-04-01Clinical Trial Update: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating lorlatinib in patients with advanced ALK-positive non-small cell lung cancer after progression on first-line second…
-
CLINICAL_TRIALS trial_result · 2025-04-01Clinical Trial Update: Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer [NA]
A completed trial evaluated whether hypofractionated radiation therapy can enhance immunotherapy response in metastatic non-small cell lung …
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] [Phase 3]
A Phase 3 study (IMpower010) evaluating atezolizumab versus best supportive care after chemotherapy in non-small cell lung cancer has posted…
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors [Phase 1, Phase 2]
This clinical trial update describes evaluation of the PET tracer [18F]AlF-NOTA-PCP2 for PD-L1 detection across malignant tumors, including …
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
A Pfizer-sponsored study in Norway evaluating the effectiveness of cancer medicines in patients with metastatic non-small cell lung cancer h…
-
CLINICAL_TRIALS trial_result · 2025-03-28Clinical Trial Update: Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors [Phase 2]
Phase 2 study evaluating upfront afatinib with concurrent chemotherapy followed by osimertinib with concurrent chemotherapy in untreated EGF…
-
CLINICAL_TRIALS trial_result · 2025-03-26Clinical Trial Update: ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating alectinib for pretreatment RET-rearranged advanced non-small cell lung cancer has been terminated; results have bee…
-
CLINICAL_TRIALS trial_result · 2025-03-26Clinical Trial Update: A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer [Phase 1]
Phase 1 study of RGX-104 in patients with advanced lung and endometrial cancer has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-26Clinical Trial Update: Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC [Phase 2]
Phase II neoadjuvant and adjuvant trial of capmatinib in non-small cell lung cancer was terminated, with results posted on 2025-03-26.
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer [Phase 1, Phase 2]
This update reports results from a Phase I/II trial of a triple-drug combination (nivolumab, ipilimumab, and nintedanib) for non-small cell …
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC [Phase 4]
Phase 4 trial update evaluating afatinib followed by osimertinib versus osimertinib alone in EGFR-mutated, T790M mutation-negative non-squam…
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA [Phase 2]
A phase 2 trial of Tusamitamab ravtansine in non-small cell lung cancer patients with low to moderate CEACAM5 expression and high circulatin…
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) [Phase 1]
Fortitude-201 (bemarituzumab) is a Phase 1 trial evaluating bemarituzumab alone or in combination with other anti-cancer therapies in FGFR2b…